+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 113 Actively Recruiting clinical trials

S

Actively Recruiting

This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.

Age: 50Years - 80YearsAll GendersPhase 2
140 locations
P

Actively Recruiting

Researchers are evaluating the best way to combine chemotherapy and radiation therapy for children and young adults with localized non-germinomatous germ cell tumors NGGCT in the brain. The study aims to optimize radiation treatment for patients who respond well to initial chemotherapy and to use higher dose chemotherapy followed by radiation for those who do not respond as well. This phase II trial focuses on how tumors respond to initial chemotherapy to decide the next treatment steps, aiming to reduce side effects and improve disease control. Participants receive induction chemotherapy with drugs like carboplatin, etoposide, ifosfamide, and thiotepa over up to six cycles, repeated every 21 days if no disease progression occurs. Based on their response, patients are assigned to one of two plans Plan A involves radiation therapy to the ventricles and spinal canal WVSCI, while Plan B includes high-dose chemotherapy with stem cell transplant followed by craniospinal radiation. Some patients may undergo second-look surgery to guide treatment decisions. During the study, participants have MRIs, cerebrospinal fluid and blood samples collected, and complete questionnaires assessing cognitive and behavioral functions. Researchers monitor tumor response, progression-free survival, overall survival, and side effects over up to 10 years. The study also compares outcomes based on radiation type and its effects on growth and blood counts, aiming to improve long-term quality of life for patients.

Age: 3Years - 29YearsAll GendersPhase 2
170 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
E

Actively Recruiting

Researchers are evaluating combination chemotherapy treatments for patients with newly diagnosed diffuse anaplastic Wilms tumors DAWT and relapsed favorable histology Wilms tumors FHWT. This phase II trial aims to compare different chemotherapy regimens to see if adding drugs like vincristine and irinotecan improves survival outcomes for these patients, based on historical data. The study also explores kidney toxicity, genetic factors, and surgical outcomes related to these tumors. Patients are assigned to one of two treatment groups. Arm I Regimen UH-3 involves multiple cycles of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan administered intravenously every 21 days with radiation therapy as needed. Arm II Regimen ICECycloTopo includes cycles of carboplatin, etoposide, ifosfamide, cyclophosphamide, and topotecan given intravenously every 21 days with surgery andor radiation as clinically indicated. Both groups undergo various imaging scans and biopsies throughout treatment. Participants are closely monitored with CT, PET, X-rays, MRI, ultrasound, bone scans, blood tests, and biopsies during the trial. After treatment, follow-up visits occur every 3 months for the first two years, then every 6 months for years 3 and 4, and once at year 5. The primary outcomes measured are event-free survival and overall survival up to five years. The study also collects blood, urine, and tumor tissue samples for future research and monitors treatment side effects and kidney function.

Age: 0 - 30YearsAll GendersPhase 2
205 locations
C

Actively Recruiting

This trial evaluates treatments for children and young adults aged 2 to 21 with newly diagnosed or untreated low-grade glioma LGG that does not have a BRAFV600E mutation or systemic neurofibromatosis type 1. The study aims to compare the effects of selumetinib, an oral drug that blocks enzymes needed for cell growth, with the standard chemotherapy regimen of carboplatin and vincristine. The main goal is to determine if selumetinib is as effective as the standard treatment in preventing disease events and to see if it improves quality of life. Participants are randomly assigned to one of two treatment groups. One group receives vincristine and carboplatin intravenously during an induction phase followed by maintenance cycles every 42 days for up to 8 cycles. The other group takes selumetinib orally twice daily in 28-day cycles for up to 27 cycles. Both groups undergo regular blood collection and MRI scans throughout treatment. The selumetinib group also has heart function evaluated by echocardiography at the start. During the study, participants will have assessments including visual acuity tests, motor function evaluations, quality of life and cognitive function questionnaires. Follow-up visits occur every 3 months for the first year, then every 6 months for years 2 and 3, and annually thereafter up to 10 years. The primary outcome measured is event-free survival over this period. The study also collects tumor and blood samples to explore genetic factors related to treatment response.

Age: 2Years - 21YearsAll GendersPhase 3
132 locations
P

Actively Recruiting

Researchers are evaluating treatments for children and young adults with low-risk and average-risk medulloblastoma, a type of brain cancer. This phase III trial aims to test two main ideas whether adding sodium thiosulfate STS to standard chemotherapy and radiation can reduce hearing loss caused by cisplatin in average-risk patients, and whether a less intense radiation therapy can be as effective for low-risk patients while reducing side effects. The study also compares outcomes to previous treatments to ensure survival and recurrence rates are not negatively affected. Participants receive radiation therapy daily for 6 weeks and weekly vincristine during treatment weeks. Maintenance therapy begins about 4 weeks later and includes cycles of oral lomustine, intravenous cisplatin, intravenous sodium thiosulfate, cyclophosphamide, and vincristine given on specific days and cycles over several months. Patients undergo MRI scans and cerebrospinal fluid collections throughout the study, with optional blood samples. After treatment, follow-up visits occur regularly for up to 10 years. Throughout the study, participants have hearing tests, brain scans, and lab tests to monitor effects and side effects. Researchers assess hearing loss, event-free and overall survival, kidney function, neurocognitive outcomes, quality of life, and social factors. Hearing loss is evaluated shortly after treatment and over time. This long-term monitoring helps understand the safety and impact of the treatments, with total involvement lasting up to 10 years after starting therapy.

Age: 4Years - 21YearsAll GendersPhase 3
111 locations
C

Actively Recruiting

Researchers are evaluating the effects of nivolumab combined with blinatumomab compared to blinatumomab alone in patients with first relapse B-cell acute lymphoblastic leukemia B-ALL, including those with Down syndrome. This phase II trial aims to assess event-free survival and safety in children and young adults aged 1 to under 31 years. The study also explores remission rates and adverse events related to these treatments. Participants receive different combinations of blinatumomab, nivolumab, dexamethasone, methotrexate, and other chemotherapy drugs depending on their assigned group or arm. Treatment cycles generally last 36 to 37 days and may repeat up to two cycles if no disease progression or unacceptable toxicity occurs. Additional therapies like radiation and intrathecal chemotherapy are given based on disease characteristics. Down syndrome patients have a specific treatment arm with tailored medication schedules. Throughout the study, participants undergo lumbar punctures, bone marrow biopsies and aspirations, and collection of blood, urine, and cerebrospinal fluid for monitoring. Follow-up visits occur every three months for one year after treatment completion to assess outcomes such as minimal residual disease negative remission and event-free survival. Safety and tolerability are closely monitored during therapy and follow-up.

Age: 1Year - 30YearsAll GendersPhase 2
227 locations
C

Actively Recruiting

Researchers are investigating treatments for newly diagnosed acute myeloid leukemia AML in children and young adults, with or without mutations in the FLT3 gene. This Phase III trial compares standard chemotherapy, which includes daunorubicin, cytarabine, and gemtuzumab ozogamicin, to therapy using a special formulation called CPX-351, which contains daunorubicin and cytarabine designed to stay longer in the bone marrow. The study also evaluates adding gilteritinib, a drug that may block abnormal FLT3 gene function and slow cancer growth, especially in patients with FLT3 mutations. The goals include comparing treatment effects, studying heart function during therapy, and assessing neurocognitive outcomes. Participants receive treatment based on risk groups and FLT3 mutation status, assigned to different study arms. Treatments include various combinations of chemotherapy drugs given intravenously, intrathecally, or orally, such as CPX-351, daunorubicin, cytarabine, gemtuzumab ozogamicin, dexrazoxane, etoposide, mitoxantrone, and gilteritinib. Treatment phases include induction, intensification, and for some, hematopoietic stem cell transplantation HSCT. Intrathecal therapies address central nervous system involvement. Gilteritinib is administered orally over extended periods in certain groups. The study also involves optional neurocognitive testing. Throughout the study, participants undergo regular assessments including blood and bone marrow samples, imaging scans like MRI and PET, and cardiac function tests such as echocardiograms. Researchers monitor minimal residual disease, survival rates, heart health, and neuropsychological function. Safety and adverse events are tracked up to three years, with some patients receiving long-term gilteritinib maintenance. The overall participation may last several years, allowing detailed evaluation of treatment impact and side effects.

Age: 6Months - 21YearsAll GendersPhase 3
206 locations
C

Actively Recruiting

Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.

Age: 5Years - 60YearsAll GendersPhase 3
419 locations
P

Actively Recruiting

Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
329 locations

1-10 of 113

1